Hyman Charles D Gilead Sciences, Inc. Transaction History

Hyman Charles D

$1.79 Billion
Q2 2024

A detailed history of Hyman Charles D transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Hyman Charles D holds 5,476 shares of GILD stock, worth $491,525. This represents 0.02% of its overall portfolio holdings.

Number of Shares

5,476

Previous 5,476 -0.0%

Holding current value

$491,525

Previous $401,000 6.48%

% of portfolio

0.02%

Previous 0.02%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	SELL	$71.58 - $87.29 $7,158 - $8,729	-100 Reduced 1.79%	5,476 $401,000
Q3 2023 Nov 01, 2023	SELL	$73.94 - $80.67 $24,030 - $26,217	-325 Reduced 5.51%	5,576 $417,000
Q2 2022 Aug 02, 2022	BUY	$57.72 - $65.01 $86,580 - $97,515	1,500 Added 34.08%	5,901 $365,000
Q4 2020 Feb 08, 2021	SELL	$56.65 - $64.55 $56,650 - $64,550	-1,000 Reduced 18.52%	4,401 $256,000
Q3 2020 Oct 26, 2020	SELL	$62.1 - $78.08 $2,173 - $2,732	-35 Reduced 0.64%	5,401 $341,000
Q2 2020 Aug 06, 2020	BUY	$72.34 - $84.0 $2,531 - $2,940	35 Added 0.65%	5,436 $418,000
Q1 2020 Apr 30, 2020	SELL	$62.63 - $80.22 $5,135 - $6,578	-82 Reduced 1.5%	5,401 $404,000
Q4 2019 Feb 03, 2020	BUY	$61.62 - $67.78 $62,790 - $69,067	1,019 Added 22.83%	5,483 $356,000
Q2 2019 Jul 24, 2019	SELL	$61.87 - $69.38 $9,280 - $10,407	-150 Reduced 3.25%	4,464 $302,000
Q1 2019 May 13, 2019	BUY	$62.53 - $70.05 $28,138 - $31,522	450 Added 10.81%	4,614 $300,000
Q3 2018 Nov 14, 2018	SELL	$71.28 - $78.92 $5,274 - $5,840	-74 Reduced 1.75%	4,164 $322,000
Q2 2018 Aug 06, 2018	BUY	$64.88 - $75.68 $4,801 - $5,600	74 Added 1.78%	4,238 $300,000
Q4 2017 Feb 06, 2018	BUY	$71.15 - $83.52 $78,265 - $91,872	1,100 Added 35.9%	4,164 $298,000
Q2 2017 Aug 14, 2017	BUY	N/A	3,064	3,064 $217,000

Others Institutions Holding GILD

# of Institutions

1,924

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hyman Charles D, based on Form 13F filings with the SEC.

News

Stay updated on Hyman Charles D with notifications on news.

Account